Sector Expert: Edward Stopke

Sagient Research

Image: Edward Stopke

Edward Stopke is a financial analyst with BioMedTracker and has been with Sagient Research for three years. He is responsible for day-to-day analysis with the BioMedTracker analyst team, and works with the scientific analysts to determine the financial and market impact of early-stage drugs. In his time with Sagient, Stopke has gained an understanding of the pharmaceutical and biotech development process, in order to develop revenue models for various indications. Stopke received a bachelor's degree in economics from San Diego State University.



Recent Interviews

Convert Catalysts into Profits: Sagient Research's Edward Stopke (1/22/15)
bluepetrihand580

The biotech sector is teeming with companies racing to bring the hot new drug or therapy to the marketplace. But realistically assessing the therapeutic potential of pipeline products is the healthy approach for selecting a winner. In this interview with The Life Sciences Report, Edward Stopke of Sagient Research unveils his list of companies with catalytic moments in the making.

Recent Quotes

"One smaller company I like is CPXX."

The Life Sciences Report Interview with Ed Stopke (1/22/15)
more >

"ATHX completed enrollment in its Phase 2 stroke study before the new year, so the first 90-day results will emerge in Q1/15E."

The Life Sciences Report Interview with Edward Stopke (1/22/15)
more >

"The research synergy with Gilead and Merck could prove fruitful for RNN in terms of acquisition potential."

The Life Sciences Report Interview with Edward Stopke (1/22/15)
more >

"If all goes well, CUR's NSI-189 product will move into Phase 2 development in Q2/15, so that is a good advancement opportunity."

The Life Sciences Report Interview with Edward Stopke (1/22/15)
more >



Due to permission requirements, not all quotes are shown.